TY - JOUR T1 - Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00399-2019 SP - 1900399 AU - Marilyn K. Glassberg AU - Marlies S. Wijsenbeek AU - Frank Gilberg AU - Ute Petzinger AU - Klaus-Uwe Kirchgaessler AU - Carlo Albera Y1 - 2019/01/01 UR - http://erj.ersjournals.com/content/early/2019/05/16/13993003.00399-2019.abstract N2 - Dyspnoea is a frequent and debilitating symptom in patients with idiopathic pulmonary fibrosis (IPF) and is reported as the most important factor determining their health-related quality of life (QoL) [1–3]. Previous post hoc analysis of pooled data from IPF clinical trials has shown that a worsening of dyspnoea was particularly likely in patients with more severe versus less severe disease [4]. Interestingly, it has been suggested that patients with more severe disease may experience a greater benefit from pirfenidone on categorical worsening of dyspnoea or death compared with patients with less severe disease [4]. Here, we report the results of a post hoc analysis aiming to further examine the effect of pirfenidone compared with placebo on dyspnoea severity in patients with IPF, including the change from baseline in dyspnoea over 12 months and categorical changes in dyspnoea at 12 months.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Glassberg reports grants and personal fees from Genentech, Inc, personal fees from Boehringer lngelheim, personal fees from Patara Pharma, personal fees from Bellerophon Therapeutics, outside the submitted work.Conflict of interest: Dr. Wijsenbeek reports grants and other from Hoffman Ia Roche, grants and other from Boehringer lngelheim, other from Galapagos, outside the submitted work.Conflict of interest: Dr. Gilberg reports other from null, during the conduct of the study; and Employee of F. Hoffmann-la Roche.Conflict of interest: Dr. Petzinge UP was an employee of Clinipace-Accovion GmbH - a company contracted by F. Hoffmann-La Roche, Ltd. to perform analyses of study data -at the time of this study.Conflict of interest: Dr. Kirchgaessler reports other from F. Hoffmann La Roche Ltd., during the conduct of the study.Conflict of interest: Dr. Albera reports personal fees from FibroGen, personal fees from Bayer, personal fees from Boehringer lngelheim, personal fees from GlaxoSmithKiine, personal fees from lnterMune/Roche, personal fees from MSD, personal fees from Sanofi , personal fees from F. Hoffmann-La Roche, Ltd., outside the submitted work. ER -